S-1/A: Drugs Made In America II Corp. Files S-1/A for $500M IPO

Drugs Made In America Acquisition II Corp., a blank check company, filed an amended S-1 registration statement for a $500 million initial public offering to target the pharmaceutical industry.

Summary

• Drugs Made In America Acquisition II Corp. (DMAA II) is a newly incorporated Cayman Islands exempted company formed to effect a business combination with one or more businesses, primarily in the pharmaceutical industry.
• The company is offering 50,000,000 units at $10.00 per unit, each consisting of one ordinary share and one right to receive one-tenth (1/10) of an ordinary share upon business combination consummation, aiming to raise $500,000,000.
• Underwriters have a 45-day option to purchase up to an additional 7,500,000 units to cover over-allotments.
• The sponsor, Drugs Made In America Acquisition II LLC, and Cantor Fitzgerald & Co. will purchase an aggregate of 1,200,000 private units at $10.00 per unit ($12,000,000 total) in a private placement concurrent with the IPO.
• Approximately $500,000,000 (or $575,000,000 if the over-allotment option is fully exercised) will be deposited into a U.S.-based trust account, to be invested in U.S. government treasury obligations or money market funds.
• The company has 24 months from the IPO closing to complete an initial business combination, or it will redeem public shares and liquidate.
• Management and directors, including CEO Lynn Stockwell and CFO Glenn Worman, also serve as officers and directors of Drugs Made In America Acquisition Corp. (DMAA), another SPAC currently seeking targets, creating potential conflicts of interest.
• Lynn Stockwell, the sole member of the sponsor, acquired 14,375,000 founder shares for a nominal price of $35,000 (approximately $0.0024 per share), leading to significant dilution for public shareholders.
• The company will reimburse its sponsor $10,000 per month for office space and administrative support and will repay up to $325,000 in loans from the sponsor for offering-related and organizational expenses.
• As of June 30, 2025, the company had a working capital deficit of $315,944 and a net loss of $97,400 for the six months ended June 30, 2025, and a net loss of $151,719 for the period from inception (August 23, 2024) through December 31, 2024.
• The company is an emerging growth company and a smaller reporting company, taking advantage of reduced reporting requirements and an extended transition period for new accounting standards.

Sentiment

Score: 4

Explanation: The filing outlines a standard SPAC IPO with a clear industry focus and an experienced management team. However, significant conflicts of interest due to management's involvement in another active SPAC, the substantial dilution for public shareholders from founder shares, and the ongoing Chapter 11 proceedings and litigation related to the CEO's other company introduce considerable risks and uncertainties. The company's current working capital deficit also highlights its reliance on the IPO for continued operations.

Positives

• The management team possesses extensive experience and a broad network within the pharmaceutical industry, which is expected to aid in identifying suitable acquisition targets.
• The business strategy focuses on mitigating U.S. medical supply chain risks by investing in companies that reduce reliance on foreign pharmaceutical production through on-shoring advanced domestic manufacturing.
• The post-business combination company aims for end-to-end capability from plant-based raw material production for Active Pharmaceutical Ingredients (APIs) to drug manufacturing and direct patient prescriptions, targeting a $44 billion plant-based production segment, API market, and generic medications.
• The company believes its structure as an existing public company offers target businesses a more certain and cost-effective alternative to a traditional IPO, providing access to capital and equity for expansion.

Negatives

• The company is a blank check company with no operating history, no revenues, and no identified target business, making it difficult to evaluate its ability to achieve its objectives.
• Public shareholders may experience immediate and substantial dilution upon the closing of the offering due to the nominal price paid by the sponsor for founder shares (approximately $0.0024 per share vs. $10.00 per unit).
• Significant conflicts of interest exist as all directors and officers also serve in similar roles for another SPAC (Drugs Made In America Acquisition Corp. DMAA) that is also seeking business combination targets, creating a pre-existing fiduciary obligation to DMAA.
• The sponsor and management team's investment in the company (founder shares and private units) will be worthless if a business combination is not completed, potentially incentivizing them to pursue a riskier or less established target.
• The company may not be able to complete an initial business combination within the 24-month completion window, leading to liquidation and public shareholders receiving only approximately $10.00 per share (or less in certain circumstances), while rights expire worthless.
• The ability of public shareholders to redeem a large number of shares may make the company unattractive to potential targets or limit the ability to complete the most desirable business combination.
• The company is not required to obtain an independent fairness opinion for non-affiliated business combinations, meaning shareholders rely solely on the board's judgment.
• The company's founder, Lynn Stockwell, is involved in ongoing Chapter 11 bankruptcy proceedings and litigation related to Bright Green Corp. (OTC: BGXX), a company she founded and runs, which could negatively affect the company's reputation and ability to complete a business combination.
• The company had a working capital deficit of $315,944 as of June 30, 2025, raising substantial doubt about its ability to continue as a going concern without the IPO proceeds.

Risks

• The company is a newly incorporated exempted company with no operating history, no revenues, and no identified operating business as a target, providing no basis to evaluate its ability to achieve its business objective.
• Public shareholders may not have an opportunity to vote on a proposed business combination, and even if a vote is held, founder share holders' participation means a combination could be approved without majority public shareholder support (as low as 4.5% of public shares needed for approval in minimum quorum scenario).
• The company may not be able to complete a business combination if it is subject to U.S. foreign investment regulations and review by CFIUS, potentially leading to delays or prohibition.
• The ability of public shareholders to exercise redemption rights with a large number of shares may prevent the company from meeting closing conditions for a business combination or optimizing its capital structure.
• The 24-month completion window may give potential target businesses leverage in negotiations and limit due diligence time.
• Global health crises (e.g., COVID-19) and geopolitical conflicts (e.g., Russia-Ukraine, Middle East) could materially adversely affect the search for a business combination and the target's business.
• Increased competition from other SPACs may make attractive targets scarcer and increase acquisition costs.
• Changes in the market for directors and officers liability insurance could make it more difficult and expensive to complete a business combination.
• Underwriters' deferred underwriting commissions, contingent on business combination completion, may create conflicts of interest in their advisory roles.
• If the company fails to complete a business combination within the completion window, public shareholders may receive less than $10.00 per share, and rights will expire worthless.
• Purchases of shares or rights by initial shareholders, directors, officers, or affiliates in the open market or privately negotiated transactions could influence a vote on a proposed business combination and reduce public float.
• The company may acquire an early-stage, financially unstable, or unproven business, exposing it to inherent operational risks.
• The company is not required to obtain an independent fairness opinion for non-affiliated business combinations.
• Resources could be wasted on researching uncompleted acquisitions.
• The lack of industry, sector, or geographic limitation for target businesses means investors cannot ascertain specific merits or risks of a particular target's operations.
• Shareholders may face difficulties protecting their interests under Cayman Islands law, which differs from U.S. corporate law.
• The company may be required to take write-downs or write-offs after a business combination, negatively affecting financial condition and share price.
• Third-party claims against the company could reduce funds in the trust account, leading to a per-share redemption amount less than $10.00.
• The securities in the trust account could bear negative interest rates, reducing redemption value.
• If the company files for bankruptcy or winding-up, distributions to shareholders could be recovered, and directors may face fiduciary duty claims.
• The company may be deemed an investment company under the Investment Company Act, leading to burdensome compliance requirements and restricted activities.
• Nasdaq may delist the company's securities, limiting liquidity and trading.
• The company is exempt from Rule 419 blank check offering protections, meaning units are immediately tradable and there's a longer period to complete a business combination.
• Shareholders holding more than 15% of shares may lose the ability to redeem all their excess shares.
• Insufficient funds outside the trust account could hinder the search for a target business.
• The company may issue notes or other debt securities to complete a business combination, adversely affecting leverage and financial condition.
• Completing only one business combination may lead to a lack of diversification and increased risk.
• Business combinations with high complexity requiring significant operational improvements could delay or prevent desired results.
• Management may not maintain control of a target business after the initial business combination.
• The absence of a specified maximum redemption threshold means a business combination could be completed even if a substantial majority of public shareholders disagree.
• Changes in laws or regulations, or failure to comply, could adversely affect the business.
• The company may amend its charter or governing instruments without shareholder approval, potentially making it easier to complete a business combination that some shareholders do not support.
• The company may be unable to obtain additional financing for a business combination or to fund the target's operations/growth.
• The sponsor's substantial interest (20% of ordinary shares) may influence shareholder votes.
• The rights and founder shares may adversely affect the market price of ordinary shares and make a business combination more difficult.
• The offering price is more arbitrary than for an operating company.
• There is currently no market for the company's securities, and an active trading market may not develop.
• An investment may result in uncertain or adverse U.S. federal income tax consequences, including potential PFIC status.
• The share price of the combined company may decline after the initial business combination.
• The business combination and subsequent structure may not be tax-efficient.
• Reincorporation or transfer to another jurisdiction may result in taxes for shareholders or right holders.
• Cyber incidents or attacks could result in information theft, data corruption, operational disruption, and/or financial loss.

Future Outlook

The company intends to focus its search for business combination targets in the pharmaceutical industry, aiming to identify, acquire, and accelerate the growth of a company that can deliver solutions to U.S. medical supply chain issues, such as lack of visibility and drug shortages. The goal is to create a fully integrated, competitive cost business with end-to-end capability from plant-based raw material production for APIs to drug manufacturing and direct patient prescriptions, leveraging advanced technology and AI. The company expects to incur increased expenses as a public company and will generate non-operating income from interest on trust account funds.

Management Comments

• Management believes the team is well positioned to take advantage of growing investment opportunities in the pharmaceutical industry, leveraging existing relationships and networks to generate an attractive transaction for shareholders.
• Management intends to transform the target company into a widely respected industry leader by leveraging the benefits of becoming a public company, including access to finance and equity for expansion, while endeavoring to generate excellent returns for shareholders.
• Management believes the sponsor's expertise and track record in the pharmaceutical space will help mitigate legal and regulatory factors by proactively advising potential target companies.
• Management believes it is possible to mitigate risks in the U.S. medical supply chain by investing in companies that will reduce America's overreliance on foreign pharmaceutical production through strategic on-shoring of advanced domestic manufacturing technologies for critical drugs.
• Management believes the post-business combination company will be able to become a new competitive cost producer of drugs made in America, creating jobs, mitigating national security risks, and ensuring clean, pure, cost-efficient medications through a resilient supply chain.

Industry Context

The company's strategic focus on the pharmaceutical industry, particularly on-shoring advanced domestic manufacturing for critical drugs and APIs, aligns with current U.S. administration initiatives to establish a fully integrated domestic drug supply chain. This addresses identified national security risks and ongoing drug shortages, as highlighted by the United States Senate Committee Homeland Security and Governmental Affairs in March 2023. The market for plant-based production, APIs, and generic medications is estimated at $44 billion, indicating a significant addressable market for a full-spectrum producer aiming to disrupt the current market with competitive costs and supply chain resilience.

Comparison to Industry Standards

• The company's management team members, including Lynn Stockwell and Glenn Worman, have prior experience with other SPACs, such as Drugs Made In America Acquisition Corp. (DMAA) and Insight Acquisition Corp., which completed a business combination with Alpha Modus, Corp. (AMOD). This indicates experience in the SPAC model, but past performance is not indicative of future results.
• The nominal price paid by the sponsor for founder shares ($0.0024 per share) is a common feature in SPACs, but it results in significant dilution for public shareholders compared to the $10.00 per unit offering price, a standard concern in the SPAC industry.
• The 24-month completion window for a business combination is a typical timeframe for SPACs, but the increasing number of SPACs in the market suggests heightened competition for attractive targets, potentially making it harder to find a suitable acquisition compared to less competitive periods.
• The company's intention to invest in U.S. government treasury obligations or money market funds for its trust account is standard practice for SPACs to preserve capital while seeking a target.

Management Changes

Corporate Governance

Legal Proceedings

• Bright Green Corp. (BGXX), a company founded and run by Lynn Stockwell (CEO of Drugs Made In America Acquisition II Corp.), entered into a Restructuring Support Agreement on January 27, 2025, and filed a voluntary Chapter 11 petition on February 22, 2025. BGXX had not generated revenues and its shares were suspended from Nasdaq trading in September 2024. The Chapter 11 proceeding is ongoing.
• In January 2021, BGXX filed a complaint against John Fikany regarding entitlement to 5,000,000 shares. Mr. Fikany counterclaimed against BGXX, Lynn Stockwell, and John Stockwell (special advisor to Drugs Made In America Acquisition II Corp.) alleging wrongful termination, fraud, negligent misrepresentation, and breach of contract. In August 2024, the court determined an oral agreement existed for Mr. Fikany to be CEO and BGXX was not entitled to cancel his shares. BGXX plans to appeal and file motions opposing Mr. Fikany's claims in the Chapter 11 proceeding. A jury trial for the counterclaim was vacated and not reset.

Related Party Transactions

• The sponsor, Drugs Made In America Acquisition II LLC, purchased 14,375,000 founder shares for $35,000 (approximately $0.0024 per share). Lynn Stockwell is the sole member of the sponsor and beneficially owns these shares.
• The sponsor and Cantor Fitzgerald & Co. committed to purchase 1,200,000 private units at $10.00 per unit ($12,000,000 total) in a private placement.
• The company will pay its sponsor or an affiliate $10,000 per month for office space, administrative, and support services, totaling $240,000 over 24 months if a business combination is not completed earlier.
• The company will repay up to $325,000 in unsecured, non-interest bearing loans from the sponsor, used for offering-related and organizational expenses. As of June 30, 2025, $297,292 was outstanding.
• The company's CFO, Glenn Worman, is a partner in an advisory firm that provides accounting services to the company, incurring $8,755 in expenses for the six months ended June 30, 2025.
• John Stockwell, special advisor and husband to CEO Lynn Stockwell, provides uncompensated advisory services, but may incur routine, minor expenses for which the company may provide reasonable reimbursements.
• The sponsor or affiliates, or certain directors and officers, may provide working capital loans up to $1,500,000, convertible into private units at $10.00 per unit at the lender's option.

Stakeholder Impact

• **Shareholders (Public)**: Face significant immediate dilution due to the nominal price paid by the sponsor for founder shares. Their investment is at risk if a business combination is not completed within 24 months, as rights will expire worthless and share redemption value may be less than $10.00. They may have limited influence on business combination decisions if a shareholder vote is not required or due to the voting power of initial shareholders.
• **Shareholders (Initial/Sponsor)**: Stand to make a substantial profit on their investment even if the public share price declines, due to the nominal purchase price of founder shares. Their interests may conflict with public shareholders in selecting a target business, as their investment becomes worthless if no business combination is completed.
• **Employees (Post-Combination)**: The company aims to create jobs through on-shoring pharmaceutical production, which could benefit the U.S. workforce. Key personnel of a target business may or may not remain with the combined entity, potentially impacting operations.
• **Customers/Patients (Post-Combination)**: The strategic focus on a resilient U.S. drug supply chain and competitive cost production aims to ensure access to clean, pure, cost-efficient medications, potentially benefiting patients and healthcare providers by mitigating drug shortages.
• **Creditors**: Funds in the trust account could be subject to claims from creditors if the company liquidates, potentially reducing the amount available for public shareholder redemptions. The sponsor has agreed to indemnify the company against certain third-party claims to protect the trust account.

Next Steps

• The company will proceed with its initial public offering of 50,000,000 units.
• The units are expected to begin trading on Nasdaq under the symbol DMIIU on or promptly after the prospectus date.
• Ordinary shares (DMII) and rights (DMIIR) will begin separate trading on the 52nd day following the prospectus date, or earlier if Cantor Fitzgerald & Co. allows.
• The company will file a Current Report on Form 8-K with an audited balance sheet reflecting IPO proceeds promptly after closing.
• Management will identify potential acquisition targets in the pharmaceutical industry, leveraging existing relationships and market research.
• The company will conduct due diligence on potential acquisition targets, including financial, operational, and legal reviews.
• The company aims to complete an initial business combination within 24 months from the IPO closing.
• The company will establish and maintain an audit committee and compensation committee, and adopt a Code of Conduct prior to the IPO closing.
• The company will maintain directors and officers insurance until the earlier of business combination completion or liquidation.
• The company will file periodic reports with the SEC as required for a public company.

Key Dates

Recommendation

The company is a blank check company with no current operations or identified target, making a 'buy' or 'sell' recommendation premature. The management team has relevant industry experience and a clear strategic focus on the pharmaceutical sector, particularly U.S. supply chain resilience, which is a positive. However, the significant conflicts of interest arising from management's involvement in another active SPAC, the substantial dilution from founder shares, and the ongoing legal and bankruptcy issues related to the CEO's other venture introduce considerable uncertainty and risk. Investors should 'hold' and await further developments, specifically the identification of a target business and more detailed financial projections, while closely monitoring how the company addresses its inherent conflicts and legal exposures.

Keywords

SPAC, Blank Check Company, Pharmaceutical Industry, IPO, SEC Filing, Business Combination, Acquisition, Merger, Healthcare, Drug Supply Chain, On-shoring, Active Pharmaceutical Ingredients (API), Generic Medications, Cayman Islands, Nasdaq, S-1/A